<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>About | MultiOmics Inc.</title>

  <!-- SEO -->
  <meta name="description" content="Learn about MultiOmics Inc., developer of LiquidMammo™, a microRNA‑based blood test designed to complement imaging for earlier breast‑cancer detection.">
  <meta name="keywords" content="MultiOmics, LiquidMammo, microRNA, molecular diagnostics, early detection, liquid biopsy">

  <!-- Stylesheet -->
  /assets/css/styles.css

  <!-- Favicon -->
  /favicon.png

  <!-- Open Graph -->
  <meta property="og:title" content="About | MultiOmics Inc.">
  <meta property="og:description" content="MultiOmics Inc. develops LiquidMammo™, a microRNA‑based supplemental screening test for earlier breast cancer detection.">
  <meta property="og:type" content="website">
  <meta property="og:url" content="https://www.liquidmammo.com/about.html">
</head>

<body>

<!-- ======================================
     MINIMAL HEADER (← Home)
======================================= -->
<header class="container" role="banner">
  <nav aria-label="Main">
    /index.html← Home</a>
  </nav>
</header>


<!-- ======================================
     HERO
======================================= -->
<section class="hero-tight">
  <div class="container grid-2">

    <div>
      <span class="eyebrow">About MultiOmics Inc.</span>
      <h1>Advancing earlier, more equitable breast‑cancer detection</h1>
      <p class="small">
        MultiOmics Inc. develops <strong>LiquidMammo™</strong>, a microRNA‑based blood test
        designed to complement imaging across diverse patient populations.
      </p>
    </div>

    <div>
      /assets/logos/multiomics-logo.png
    </div>

  </div>
</section>


<!-- ======================================
     WHO WE ARE
======================================= -->
<section class="section">
  <div class="container grid-3">

    <div class="card">
      <h3>Who we are</h3>
      <p class="small">
        MultiOmics Inc. is a molecular diagnostics company transforming
        circulating microRNA signals into practical tools for earlier disease
        detection. Our team spans molecular biology, biostatistics, clinical
        diagnostics, and population‑level screening research.
      </p>
    </div>

    <div class="card">
      <h3>Our mission</h3>
      <p class="small">
        We aim to improve breast‑cancer screening by complementing mammography
        with biologically driven signals — particularly in dense‑breast populations
        where imaging sensitivity limits early detection.
      </p>
    </div>

    <div class="card">
      <h3>Where we operate</h3>
      <p class="small">
        MultiOmics Inc. is headquartered in Washington, DC, and operates from
        LabCentral in Cambridge, MA — a leading MIT‑adjacent innovation hub.
      </p>
    </div>

  </div>
</section>


<!-- ======================================
     SCIENCE & TECHNOLOGY
======================================= -->
<section class="panel-light section">
  <div class="container">

    <h2>The science behind LiquidMammo™</h2>

    <div class="grid-3">

      <div class="card">
        <h3>microRNA biology</h3>
        <p class="small">
          LiquidMammo analyzes dysregulation patterns in circulating microRNAs —
          small non‑coding RNA molecules associated with tumor biology — to detect
          early molecular changes that may precede imaging findings.
        </p>
      </div>

      <div class="card">
        <h3>Multi‑marker panel</h3>
        <p class="small">
          The proprietary panel integrates multiple microRNA markers to improve
          robustness, reproducibility, and performance across heterogeneous
          patient populations.
        </p>
      </div>

      <div class="card">
        <h3>Clinical rationale</h3>
        <p class="small">
          Layering molecular insight with imaging supports more confident
          interpretation and clinical decision‑making, especially in patients
          with dense breast tissue.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- ======================================
     TEAM & ADVISORS
======================================= -->
<section class="section">
  <div class="container">

    <h2>Leadership &amp; scientific advisors</h2>

    <div class="grid-3">

      <div class="card">
        <h3>Founding team</h3>
        <p class="small">
          Expertise across molecular diagnostics, assay development, epidemiology,
          and biostatistics.
        </p>
      </div>

      <div class="card">
        <h3>Clinical advisors</h3>
        <p class="small">
          Breast‑imaging radiologists and oncology experts guide screening,
          diagnostic workflows, and clinical deployment.
        </p>
      </div>

      <div class="card">
        <h3>Academic collaborations</h3>
        <p class="small">
          MultiOmics partners with academic researchers to refine assay
          performance, validate utility, and support diverse‑population analysis.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- ======================================
     IMPACT
======================================= -->
<section class="panel-light section">
  <div class="container grid-3">

    <div class="card">
      <h3>Impact for patients</h3>
      <p class="small">
        A non‑invasive complement to imaging that helps clarify uncertain results,
        reduce false positives, and support earlier detection in dense‑breast
        populations.
      </p>
    </div>

    <div class="card">
      <h3>Impact for clinicians</h3>
      <p class="small">
        Standardized molecular insights that integrate directly into clinical
        workflows with minimal burden.
      </p>
    </div>

    <div class="card">
      <h3>Business opportunity</h3>
      <p class="small">
        Growing demand for liquid‑biopsy early detection provides scalable CLIA LDT
        pathways for rapid iteration and clinical validation.
      </p>
    </div>

  </div>
</section>


<!-- ======================================
     FOOTER
======================================= -->
<footer role="contentinfo">
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC,
        and operates out of LabCentral in Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end; text-align:right;">
      /assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br/>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
